Biovie (BIVI) Other Working Capital Changes (2022 - 2026)
Biovie (BIVI) posted Other Working Capital Changes of -$19198.0 for Q1 2026, down 7.76% sequentially from -$17815.0 in Q4 2025, and down 23.1% YoY from -$24963.5 in Q1 2025.
Biovie (BIVI) Other Working Capital Changes (2022 - 2026) Analysis & Trends
Biovie has reported Other Working Capital Changes for 5 years, with the latest figure at -$19198.0 in Q1 2026.
- Quarterly Other Working Capital Changes fell 23.1% year-over-year to -$19198.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$70713.0 (down 23.75% YoY) and the FY2025 annual result came in at -$60343.0, down 27.72% from the prior year.
- Other Working Capital Changes eased to -$19198.0 in Q1 2026 per BIVI's latest filing, from -$17815.0 in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $1.4 million in Q3 2023 and troughed at -$1.2 million in Q4 2023.
- A 5-year average of $85421.4 and a median of $14810.0 in 2024 frame the typical range for Other Working Capital Changes.
- The sharpest annual moves came in 2023 and 2024: Other Working Capital Changes decreased 15.54% in 2023, then plunged 31.41% in 2024.
- Over 5 years, Other Working Capital Changes stood at -$9462.0 in 2022, then slipped by 15.56% to -$10934.0 in 2023, then slumped by 31.41% to -$14368.0 in 2024, then dropped by 23.99% to -$17815.0 in 2025, then retreated by 7.76% to -$19198.0 in 2026.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered -$19198.0, -$17815.0, and -$17164.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20,287.00 |
| Jun 30, 2026 | -20,287.00 |
| Jun 30, 2026 | -20,287.00 |
| Mar 31, 2026 | -19,198.00 |
| Mar 31, 2026 | -19,198.00 |
| Mar 31, 2026 | -19,198.00 |
| Dec 31, 2025 | -17,815.00 |
| Dec 31, 2025 | -17,815.00 |
| Dec 31, 2025 | -17,815.00 |
| Sep 30, 2025 | -17,164.00 |
| Sep 30, 2025 | -17,164.00 |
| Sep 30, 2025 | -17,164.00 |
| Jun 30, 2025 | -16,536.00 |
| Jun 30, 2025 | -16,536.00 |
| Jun 30, 2025 | -16,536.00 |
| Mar 31, 2025 | -15,596.00 |
| Mar 31, 2025 | -15,596.00 |
| Mar 31, 2025 | -15,596.00 |
| Dec 31, 2024 | -14,368.00 |
| Dec 31, 2024 | -14,368.00 |